Drugs / SM-88
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02562612 | Oct 2022 → Oct 2023 | breast cancer | Tyme, Inc | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04720664 | Sep 2021 → Feb 2023 | hormone receptor-positive breast cancer | Georgetown University | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03512756 | Mar 2018 → Dec 2021 | malignant pancreatic neoplasm | Tyme, Inc | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04229004 | Jan 2020 → Feb 2025 | pancreatic adenocarcinoma | Pancreatic Cancer Action Network | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SM-88 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03512756 ↗ |
| Route | Oral | “oral administration of a cocktail combination of 4 drugs” NCT02562612 ↗ |